Cancer Advisor

Quick Answer Dr. Thomas Seyfried , a biologist at Boston College, argues that cancer is primarily a mitochondrial metabolic disease rather than a genetic one. His core treatment framework — the Press-Pulse protocol — pairs a therapeutic ketogenic diet that restricts glucose and glutamine (the "press") with pulsed adjuncts like glutaminase-inhibiting drugs, hyperbaric oxygen, or fasting (the "pulse"). Mechanistic and preclinical evidence is strong; human evidence is a mix of promising case reports and small, mostly inconclusive trials — including a 2026 randomized pancreatic cancer trial that showed a survival trend without reaching statistical significance. Most integrative oncologists treat metabolic therapy as a physician-supervised adjunct to, not a replacement for, standard cancer care. In This Guide Who Is Thomas Seyfried? The Case Against Standard-of-Care Statistics Diet and Cancer: Why Food Isn't Neutral Cutting Off Cancer's Fu...

Introduction: The Promise and the Gap Metabolic therapy in oncology — encompassing ketogenic diets, caloric restriction, glucose-lowering drugs like metformin, and combinations thereof — has moved from fringe hypothesis to serious clinical inquiry over the past decade. Yet a fundamental question persists in both the research literature and the clinic: which patients actually respond? The answer is neither simple nor universal. Response to metabolic interventions appears to depend on tumor genetics, metabolic phenotype, immune context, and patient physiology. Understanding these variables is no longer optional for clinicians or researchers seeking to apply these approaches responsibly. This article reviews the current evidence on patient selection for metabolic therapy, identifies the biomarkers and tumor characteristics most associated with response, and highlights where the field still lacks clarity. What Is Metabolic Therapy in Cancer? Metabolic therapy refers to any intervention tha...

Abstract Background: Conventional metabolic oncology frameworks often group glucose-dependent and glutamine-dependent tumours under a singular "Warburg Effect" umbrella. However, distinct metabolic wiring requires precise patient selection to avoid off-target therapeutic failures. Methods: By analyzing substrate flux, PET tracer avidity ( 18 F-FDG vs. amino acid/glutamine tracers), and intracellular enzymatic expression, we constructed a 4-category classification matrix to guide adjunctive metabolic protocols alongside standard-of-care oncology. Results: Tumour bioenergetics stratify into four distinct phenotypes: Category 1: Glycolytic-Dependent (Glucose-Addicted); Category 2: Glutamine-Dependent (Glutaminolysis-Driven); Category 3: Hormone & Insulin-Driven; and Category 4: OxPhos-Reliant & Plastic Solid Tumours. Conclusion: Differentiating glucose addiction from glutamine addiction...